Bergs Securities acted as financial adviser in the SEK 132m rights issue in Enzymatica.

Bergs Securities acted as financial adviser in the SEK 132m rights issue in Enzymatica.

Enzymatica develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The products are based on the Penzyme® technology, which includes marine enzymes with unique properties. The best-selling product is ColdZyme®, a mouth spray for colds and cold-like symptoms of the upper respiratory tract. ColdZyme has been launched in over 30 markets on four continents. The strategy is to continue to grow by developing more health products, strengthening the company’s position in existing markets and expanding into new geographic markets through established partners.